Developer of a biomedical informatics and data management platform designed to analyze DNA-sequencing data.
Developer of a biomedical informatics and data management platform designed to analyze DNA-sequencing data.
Discovery Tools (Healthcare)📍 San Francisco, CAFounded 2009
Current Valuation
$620M
as of 2022-Q1
PRIVATE
QL Price
$1.0B
+67% vs last round
QuantLogix's current estimate for DNAnexus, published 2026-09-27 — above the last disclosed round of $620M (2022-Q1).
Confidence
medium
Basis
secondary led
What backs this price
Last disclosed round
$620M
2022-Q1
weight 0.04
Secondary market print
$1.1B
2026-06-27
weight 0.58
How this price has held up
No round has priced for DNAnexus since QuantLogix began publishing a price for it, so there is nothing to grade yet. The claim above is on the record from 2026-09-27 and will be graded against the next priced round. See the full accuracy record →
Which publicly-traded funds already hold it, what $10,000 buys, and whether any route is open to you.
Cite this price as QuantLogix QL Price, DNAnexus, 2026-09-27 (36c8241b9f6322e8).
The id pins this exact claim, so a citation stays checkable after the price moves.
Model estimate for research — not a quote, target price, or investment advice.
IPO Outlookprivate
Is DNAnexus going public?
No. DNAnexus is private and has not filed to go public. There is no S-1 on file.
What is DNAnexus' valuation in 2026?
DNAnexus is valued at $620M as of 2022-Q1, set by its Series I ($200M, Mar 2022). That is the last confirmed mark, not a live price — private shares do not trade continuously.
Has DNAnexus filed an S-1?
No public S-1 is on file for DNAnexus.
How much has DNAnexus raised?
DNAnexus has raised $478.73M in total, most recently a Series I of $200M in Mar 2022.
Is DNAnexus publicly traded — can you buy DNAnexus stock?
No. DNAnexus is a private company — its shares are not listed on any exchange and there is no ticker. The routes to exposure are pre-IPO secondary marketplaces and funds (accredited investors), employee tender offers when the company runs one, and public companies with read-through exposure. QuantLogix maps every route it can verify for DNAnexus on its Pre-IPO Access Desk.
Answers are derived from the roster record shown on this page — filing status, last round and confirmed marks. Where the record is silent, the answer says so rather than guessing.
Company Profile
Founded
2009
HQ
San Francisco, CA
Employees
284
Total Raised
$478.73M
Last Round
Series I — $200M (Mar 2022)
IPO Status
private
Fundraising Status
Series I · $200M · 4y 6mo ago
privateTotal raised $478.73M
Secondary Market
Implied price / share
$1.05
Last round price / share
$0.61
vs last round
+72.1%
Last round price vs secondary price
Secondary price return by period
Implied per-share price from private secondary transactions, as of Jun 2026. This is a point estimate, not a quote — the feed carries no bid, ask or spread, and a secondary print is evidence of what someone paid on that date rather than a live market. Compare across every tracked name →
Latest Funding Round
Round
Amount
Date
Lead Investor
Post-Money
Series I
$200M
Mar 2022
—
$620M
Vertical Intelligence — Biotech / Gene Therapy
No name-verified sponsor record on ClinicalTrials.gov for DNAnexus — trials may run under a different legal entity, a partner sponsor, or not yet exist. Absence of a registry match is reported as-is, never guessed around.
Checked clinicaltrials.gov as of 2026-09-19. Re-checked weekly.
Talent Signal
Hiring trend
▶ Hiring steady
0% vs 2026-08
Open roles
10
via careers page
Product-build share
60%
engineering, research, product, design
Trajectory
strengthening
product-led hiring — 60% of open roles build product; the rest are go-to-market and G&A.
Recent senior hire: 1 senior hire (CTO).
Open roles by month
Open roles by function
■ product-building ■ go-to-market / G&A
Key Executive Moves
INPieter De LeenheerCTO · 2026-08-25
From trusted-source news extraction (deep-enrich pipeline); dates approximate publication, not effective date.
Counted from DNAnexus's live job board as of 2026-09-16; role functions classified from posting titles. Open-role counts are an activity signal, not headcount. Refreshed monthly.
MedicalBioinformaticsBiotechnologyCloud Computing
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of 2022-Q1. Refreshed quarterly.